|Mr. Mark D. Perrin||Chairman and Chief Exec. Officer||741.94k||N/A||60|
|Dr. Thomas R. Ulich M.D.||Chief Scientific Officer||463.28k||N/A||64|
|Ms. Pamela J. Stahl||Chief Commercial Officer||660.94k||N/A||51|
|Dr. Robert S. Langer Jr., Ph.D., Sc.D.||Co-Founder and Member of Scientific Advisory Board||N/A||N/A||68|
|Dr. Joseph Philip Vacanti M.D.||Co-Founder||N/A||N/A||68|
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is based in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 9.